We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




New Class of Compounds May Revive Failing Hearts

By HospiMedica staff writers
Posted on 08 Sep 2004
Researchers have developed a new class of nitric oxide (NO) compounds called nitroxyl precursors that produce hydrogen nitrite (HNO) and in early studies appear to play a role in protecting the cardiovascular system from further damage during heart failure and in restoring function to affected organs.

When a compound called Angeli's salt, which generates HNO, was administered to normal, conscious dogs and those with heart failure, the treatment doubled the ability of the dog hearts to pump and enhanced their ability to relax between contractions. More...
Prior research has also shown that nitroxyl precursors appear to be very good candidates to treat failing hearts characterized by pressure overload, contractile function, and delayed relaxation.

However, a main reaction of nitroxyl is dimerization. "So, compounds that release HNO at faster rates generate higher initial concentrations of it and therefore may result in HNO being consumed by the dimerization reaction, rather than being available to elicit the desired physiologic response,” explained John P. Toscano, professor in the chemistry department at the Krieger School of Arts and Sciences at Johns Hopkins University (Baltimore, MD, USA; www.jhu.edu).

Therefore, two new derivatives of nitric oxide, one a pure HNO donor and one a pure NO donor, have been tested on dogs. "This looks promising,” said Prof. Toscano. "We know that NO is an important biological molecule, and we are just beginning to learn that HNO may, in potentially very different ways, be just as important.”





Related Links:
Johns Hopkins U.

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Bipolar Coagulation Generator
Aesculap
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.